Federal contract award
0034
IGF::OT::IGF THERAPEUTIC HUMAN MIRNAS FOR USE AS ANTI-VIRAL DRUGS FOR INFLUENZA A INFECTION PROPHYLAXIS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | FA8650 USAF AFMC AFRL PZL AFRL/PZL |
| NAICS | 541712 |
| PSC | AN92 — OTHER MEDICAL - APPLIED RESEARCH/EXPLORATORY DEVELOPMENT |
| Parent award / vehicle | FA865012D6280 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $207.9K |
| Current contract value | $207.9K |
| Potential contract value / ceiling | $207.9K |
| Start date | Jun 11, 2015 |
| Current end date | Nov 14, 2016 |
| Potential end date | Mar 25, 2025 |
| Latest award activity | Mar 25, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Mar 25, 2025 | 4 | $1.7K | QUASAR - FINALIZED INCREMENTAL FUNDING |
| Mar 24, 2025 | 3 | $-9 | TO 34 THERAPEUTIC HUMAN MIRNAS FOR USE AS ANTI-VIRAL DRUGS FOR INFLUENZA INFECTION PROPHYLAXIS - FIN |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.